Maze Therapeutics, Inc. MAZE
26.05
(0.16)
(0.61%)
as of 25 Sep
- Market cap
- $1.5B
- P/E
- 0.0×
Follow MAZE
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
P/E ratio |
— | 1.01 | — | — |
P/S ratio |
— | 0.00 | — | — |
P/FCF ratio |
— | 0.52 | — | — |
P/Operating CF |
— | (1.73) | — | — |
P/B ratio |
— | 0.00 | — | — |
Price to Tangible BV |
— | 0.00 | — | — |
EV/Sales |
— | 0.00 | — | — |
EV/EBITDA |
— | 0.00 | — | — |
EV/Operating CF |
— | (1.82) | — | — |
EV/FCF |
— | (1.84) | — | — |
Quick Ratio |
15.16 | 9.52 | 1.79 | 4.81 |
Current Ratio |
15.50 | 9.76 | 2.09 | 5.11 |
Net Debt/EBITDA |
2.43 | (3.23) | 0.10 | 0.93 |
Debt/Assets |
0.00% | 0.00% | 28.08% | 0.00% |
Debt/Equity |
0.00 | 0.00 | (0.05) | 0.00 |
Asset Turnover |
0.00 | 1.07 | 0.00 | — |
Operating CF/Net income |
0.85 | 22.31 | 0.86 | 0.86 |
Capex/Depreciation |
(0.33) | (0.35) | (0.11) | (0.51) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 |
| (598.95%) | (0.99%) | 30.60% | 0.00% | |
| (41.12%) | 2.18% | (90.68%) | 0.00% | |
ROIC |
(684.43%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(39.47%) | 1.81% | (376.95%) | (117.56%) |
Average Days of Receivables |
— | 0.00 | — | — |
Research and Development Expense of Revenue |
0.00% | 49.85% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 15.77% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 5.76% | 0.00% | 0.00% |
Graham Net Nets |
— | (9.02) | — | — |
Graham Number |
— | 0.00 | — | — |
Earnings Yield |
— | 98.67% | — | — |
Free Cash Flow Yield |
— | 192.85% | — | — |
Revenue per Share |
0.00 | 69.91 | 0.00 | 0.00 |
Operating CF per Share |
(2.60) | 31.70 | (37.95) | (49.38) |
Capex per Share |
(0.02) | (0.48) | (0.19) | (0.98) |
Free Cash Flow per Share |
(2.62) | 31.22 | (38.14) | (50.36) |
Cash per Share |
7.96 | 82.14 | 12.74 | 49.74 |
Shareholders Equity per Share |
8.26 | (129.88) | (163.40) | (140.60) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
8.26 | (129.88) | (163.40) | (140.60) |
Free Cash Flow |
(112.73) | 74.81 | (87.27) | (101.17) |
Working Capital |
327.16 | 181.00 | 17.79 | 85.37 |
Capital Expenditures |
(0.79) | (1.15) | (0.44) | (1.97) |
Net Current Asset Value |
307.56 | (350.05) | (411.24) | (326.27) |
EV/EBIT |
— | 0.00 | — | — |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 2.03% | 0.00% | 0.00% |
Price to Operating Income |
— | 0.67 | — | — |
| Other line items | ||||
Depreciation/Fixed assets |
0.48 | 0.49 | 0.46 | 0.31 |
Cash ROIC |
(16.79%) | (60.58%) | 29.47% | 61.14% |
Accounts Receivable Turnover |
— | 0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
1.87 | 1.98 | 1.80 | — |
Average Assets |
318.83 | 156.02 | 110.73 | — |
Average Common Equity |
21.89 | (342.52) | (328.15) | — |
Columns are period end dates